This week in MedTech featured strong global deal activity, with cross-border acquisitions, large growth rounds, and public-market moves accelerating expansion in digital health, cardiovascular care, and AI-powered diagnostics. Details follow below.
Zylox-Tonbridge to acquire German medical technology company Optimed
Under the agreement, Zylox-Tonbridge will acquire Optimed’s equity interest in multiple steps, with an option to purchase the entire shareholding from current owners.
The acquisition is designed to accelerate global expansion by creating a unified platform that spans research and development, manufacturing, and commercialization.
Chairman and CEO Jonathon Zhong Zhao of Zylox-Tonbridge
CEO Rüdiger Hausherr of Optimed
Last week’s tracker: 4DMedical, Inquis & more
Oviva secured €200M to expand AI-enabled healthcare across Europe
The round was led by Kinnevik, with participation from Planet First Partners, A.P. Moller Holding, Lunate, EGS Beteiligungen AG, and Norrsken VC, alongside continued support from existing investor Sofina.
The round will support rising demand for reimbursed digital healthcare and help expand into chronic indications, including hypertension and type 2 diabetes, to help prevent and manage costly comorbidities. The company will also advance its AI-powered tools to better support patients and clinicians.
Co-Founder and CEO Kai Eberhardt
LivsMed completed Korean IPO worth $94M
The company plans to use its proceeds to build an integrated production base, fund R&D and strengthen related management systems to support global growth across its product portfolio.
It says that its debut as a public company led to its market capitalization surpassing approximately $1 billion.
Founder and CEO Jung Joo Lee
Medtronic to invest up to $90M in Anteris Technologies
The private placement, announced after market close, requires Medtronic to acquire a 16.0-19.99% stake in Anteris.
In addition, Anteris is proposing a $200 million underwritten public offering, with the underwriters given a 30-day option to spend $30 million to buy additional shares of common stock at the public offering price.
CEO Geoff Martha of Medtronic
CEO Wayne Paterson of Anteris Technologies
SETT invested €30M in Universal DX
The investment will help the company develop a system that combines AI, machine learning and molecular analysis to identify patterns in DNA with unique accuracy.
The project is part of SETT’s public-private partnership strategy, which is participating with this co-investment in a capital increase round in which the company has raised a total of €62M from several investment partners.
Founder Juan Martinez-Barea
TRiCares secured €20M non-dilutive financing from the EIB
The facility has been granted to provide flexible financing support for TRiCares’ research, development and innovation activities, including advancing clinical studies of Topaz, its Transfemoral Tricuspid Heart Valve Replacement (TTVR) System.
To date, implantations have taken place at major structural heart institutions across the US, with a total of 15 patients to be enrolled across 8 sites.
President and CEO Ahmed Elmouelhi
Ahead Health secured $6M to detect cancer and heart disease years earlier using AI
The seed funding round was led by RTP Global, with backing from Tiny.VC, Pareto 20, and a group of experienced founders, operators, and athletes.
The company’s AI analyses biomarkers from scans and blood data to flag signs of conditions such as cancer, cardiovascular disease, brain disorders, and endometriosis, often years earlier than traditional healthcare pathways.
Co-Founder and CEO Nick Lenten
Cancilico raised €2.5M to advance AI-powered cancer diagnostics
The investment was led by a strong consortium including High-Tech Gründerfonds, TGFS – Technologiegründerfonds Sachsen, GEDAD GmbH, and ROI Verwaltungsgesellschaft.
The funding will accelerate the company’s AI-based diagnostic software MyeloAID as a routine tool to improve the standard of care for blood cancer patients worldwide and to accelerate digital biomarker development in haematological malignancies.
Co-Founder and CEO Markus Badstübner
Ventripoint announced the closing of non-brokered units private placement
The company closed its previously announced nonbrokered private placement of anaggregate of 10,097,720 units at a price of $0.10 per unit for aggregate gross proceeds of $1,009,772.
Directors and Officers of the company (insiders) invested an aggregate of $139,340, which was 13.8% of the total proceeds.
President and CEO Hugh MacNaught
